Corixa Corp.’s stock took a dive Wednesday after the FDA said in a “complete review letter” that the company failed to provide sufficient evidence of safety and clinical benefit in its biologics license application for the non-Hodgkin’s lymphoma drug Bexxar. (BioWorld Today)